Case Overview
Keller Rohrback has filed class action complaints on behalf of plaintiffs in multiple states alleging deceptive marketing practices by companies selling cold products containing phenylephrine (“PE”). On September 11 and 12, 2023, a U.S. Food & Drug Administration (“FDA”) advisory panel concluded that over the counter (OTC) oral phenylephrine is ineffective as a nasal decongestant. Plaintiffs allege Defendants knew and/or had reason to know that their products were no more effective than placebo. These deceptive practices caused unknowing customers to spend millions of dollars on products that did not provide relief from their symptoms.
Case Status
A Conditional Transfer Order was issued on December 7, 2023, ordering the transfer of these actions to the United States District Court of the Eastern District of New York for consolidated pretrial proceedings before United States District Court Judge Brian M. Cogan. On September 23, 2024, oral argument was held on Defendants’ Motion to Dismiss Plaintiffs’ Bellwether Complaint. Limited informal discovery negotiations between the parties have begun and formal discovery will commence once the Court has ruled on Defendants’ Motion to Dismiss. On April 3, 2024, the Court appointed Keller Rohrback partner Cari Laufenberg as a member of the Plaintiffs’ Steering Committee.
CONTACT US:
For more information about this case, please email us, call us, or fill out the secure form below.